Medical Expenditures for Colorectal Cancer Diagnosis and Treatment: A 10-Year High-Level-hospital-based Multicenter Retrospective Survey in China, 2002-2011.
Jufang Shi,Guoxiang Liu,Hong Wang,Ayan Mao,Chengcheng Liu,Lanwei Guo,Huiyao Huang,Jiansong Ren,Xianzhen Liao,Yana Bai,Xiaojie Sun,Xinyu Zhu,Jialin Wang,Bingbing Song,Jinyi Zhou,Lin Zhu,Haike Lei,Yuqin Liu,Yunyong Liu,Lingbin Du,Yutong He,Kai Zhang,Ni Li,Wanqing Chen,Min Dai,Jie He
DOI: https://doi.org/10.21147/j.issn.1000-9604.2019.05.12
2019-01-01
Abstract:OBJECTIVE:Colorectal cancer (CRC) causes a substantial burden of disease in China and the evidence of economic burden triggered is fundamental for priority setting. The aim of this survey was to quantify medical expenditures and the time trends for CRC diagnosis and treatment in China. METHODS:From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 13 provinces across China. For each eligible CRC patient diagnosed from 2002 to 2011, clinical information and expenditure data were extracted using a uniform questionnaire. All expenditure data were reported in Chinese Yuan (CNY) using 2011 values. RESULTS:Of the 14,536 CRC patients included, the average age at diagnosis was 58.2 years and 15.8% were stage-I cases. The average medical expenditure per patient was estimated at 37,902 CNY [95 % confidence interval (95% CI): 37,282-38,522], and the annual average increase rate was 9.2% from 2002 to 2011 (P for trend <0.001), with a cumulative increase of 2.4 times (from 23,275 CNY to 56,010 CNY). The expenditure per patient in stages I, II, III and IV were 31,698 CNY, 37,067 CNY, 38,918 CNY and 42,614 CNY, respectively (P<0.001). Expenditure significantly differed within various subgroups. Expenses for drugs contributed the largest proportion (52.6%). CONCLUSIONS:These conservative estimates illustrated that medical expenditures for CRC diagnosis and treatment in tertiary hospitals in China were substantial and increased rapidly over the 10 years, with drugs continually being the main expense by 2011. Relatively, medical expenditures are lower for CRC in the earlier stages. These findings will facilitate the economic evaluation of CRC prevention and control in China.